Fasenra Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Benralizumab

Indications/Uses

Add-on maintenance treatment in adults w/ severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. Add-on treatment for adults w/ relapsing or refractory eosinophilic granulomatosis w/ polyangiitis (EGPA).

Click to view Fasenra detailed prescribing information

Dosage/Direction for Use

SC Asthma 30 mg every 4 wk for the 1st 3 doses, then every 8 wk thereafter. EGPA 30 mg every 4 wk.

Click to view Fasenra detailed prescribing information

Overdosage

View Fasenra overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Fasenra detailed prescribing information

Special Precautions

Permanently discontinue use in the event of a hypersensitivity reaction. Do not inj into areas w/ tender, bruised, erythematous, or hardened skin. Should not be used to treat acute asthma exacerbations. Abrupt discontinuation of corticosteroids after initiation of Fasenra therapy is not recommended. Patients w/ pre-existing helminth infections should be treated before initiating therapy w/ benralizumab. Has not been studied in patients w/ active organ-threatening or life-threatening manifestations of EGPA. Preferable to avoid use during pregnancy. Discontinue breast-feeding or discontinue/abstain from Fasenra therapy. Safety & efficacy have not been established in childn & adolescents 6-17 yr w/ asthma; childn <6 yr w/ asthma; childn & adolescents <18 yr w/ EGPA.

Click to view Fasenra detailed prescribing information

Use In Pregnancy & Lactation

Click to view Fasenra detailed prescribing information

Adverse Reactions

Pharyngitis; hypersensitivity reactions; headache; pyrexia, inj site reaction.

Click to view Fasenra detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Fasenra detailed prescribing information

Storage

View Fasenra storage conditions for details to ensure optimal shelf-life.

Description

View Fasenra description for details of the chemical structure and excipients (inactive components).

Action

View Fasenra mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.

Regulatory Classification

P₁S₁S₃

Presentation/Packing

Form

Fasenra soln for inj (pre-filled pen) 30 mg/mL

Packing/Price

1's

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig

Four Star